当前位置:杭州昊鑫生物科技股份有限公司>>MCE>>生物试剂>> HY-17589AChloroquine试剂
CAS号 | 54-05-7 | 产地 | 进口 |
---|---|---|---|
级别 | 其他 |
生物活性 | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target[1][2][3][5] |
| ||||||||||||||||||||
体外研究 (In Vitro) | Chloroquine (CHQ, 20 μM) inhibits IL-12p70 release and reduces Th1-priming capacity of activated human monocyte-derived Langerhans-like cells (MoLC). Chloroquine (20 μM) enhances IL-1–induced IL-23 secretion in MoLC and subsequently increases IL-17A release by primed CD4+ T cells[1]. Chloroquine (25 μM) suppresses MMP-9 mRNA expression in normoxia and hypoxia in parental MDA-MB-231 cells. Chloroquine has cell-, dose- and hypoxia-dependent effects on MMP-2, MMP-9 and MMP-13 mRNA expression[2]. TLR7 and TLR9 inhibition using IRS-954 or chloroquine significantly reduces HuH7 cell proliferation in vitro[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||||||
体内研究 (In Vivo) | Chloroquine (80 mg/kg, i.p.) does not prevent the growth of the triple-negative MDA-MB-231 cells with high or low TLR9 expression levels in the orthotopic mouse model[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||||||
Clinical Trial |
| ||||||||||||||||||||
分子量 | 319.87 | ||||||||||||||||||||
性状 | Solid | ||||||||||||||||||||
Formula | C18H26ClN3 | ||||||||||||||||||||
CAS 号 | 54-05-7 |
注:本产品仅用于科研,不可用于临床
请输入账号
请输入密码
请输验证码
以上信息由企业自行提供,信息内容的真实性、准确性和合法性由相关企业负责,制药网对此不承担任何保证责任。
温馨提示:为规避购买风险,建议您在购买产品前务必确认供应商资质及产品质量。